Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,533
archived clinical trials in
Chronic Obstructive Pulmonary Disease

A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated:  9/5/2017
Phoenix Medical Research Institute, LLC; Phoenix Medical Research Institute, LLC
mi
from
Peoria, AZ
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated: 9/5/2017
Phoenix Medical Research Institute, LLC; Phoenix Medical Research Institute, LLC
mi
from
Peoria, AZ
Click here to add this to my saved trials
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated:  9/5/2017
Gastonia Pharmaceutical Research
mi
from
Gastonia, NC
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated: 9/5/2017
Gastonia Pharmaceutical Research
mi
from
Gastonia, NC
Click here to add this to my saved trials
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated:  9/5/2017
Piedmont Research Partners, LLC
mi
from
Indian Land, SC
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated: 9/5/2017
Piedmont Research Partners, LLC
mi
from
Indian Land, SC
Click here to add this to my saved trials
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated:  9/5/2017
Baylor College of Medicine; Ben Taub Hospital- Guntupalli
mi
from
Houston, TX
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated: 9/5/2017
Baylor College of Medicine; Ben Taub Hospital- Guntupalli
mi
from
Houston, TX
Click here to add this to my saved trials
EAA Intake to Optimize Protein Anabolism in COPD
Essential Amino Acid Intake to Optimize Protein Anabolism in Elderly COPD Patients
Status: Enrolling
Updated:  9/7/2017
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
EAA Intake to Optimize Protein Anabolism in COPD
Essential Amino Acid Intake to Optimize Protein Anabolism in Elderly COPD Patients
Status: Enrolling
Updated: 9/7/2017
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
Smoking Cessation Versus Long-term Nicotine Replacement Among High-risk Smokers
Smoking Cessation Versus Long-term Nicotine Replacement Among High-risk Smokers
Status: Enrolling
Updated:  9/7/2017
Kansas University Medical Center
mi
from
Kansas City, KA
Smoking Cessation Versus Long-term Nicotine Replacement Among High-risk Smokers
Smoking Cessation Versus Long-term Nicotine Replacement Among High-risk Smokers
Status: Enrolling
Updated: 9/7/2017
Kansas University Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD
Status: Enrolling
Updated:  9/7/2017
GSK Investigational Site
mi
from
Newport Beach, CA
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD
Status: Enrolling
Updated: 9/7/2017
GSK Investigational Site
mi
from
Newport Beach, CA
Click here to add this to my saved trials
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD
Status: Enrolling
Updated:  9/7/2017
GSK Investigational Site
mi
from
Upland, CA
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD
Status: Enrolling
Updated: 9/7/2017
GSK Investigational Site
mi
from
Upland, CA
Click here to add this to my saved trials
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD
Status: Enrolling
Updated:  9/7/2017
GSK Investigational Site
mi
from
Sunset, LA
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD
Status: Enrolling
Updated: 9/7/2017
GSK Investigational Site
mi
from
Sunset, LA
Click here to add this to my saved trials
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD
Status: Enrolling
Updated:  9/7/2017
GSK Investigational Site
mi
from
Charlotte, NC
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD
Status: Enrolling
Updated: 9/7/2017
GSK Investigational Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD
Status: Enrolling
Updated:  9/7/2017
GSK Investigational Site
mi
from
Cincinnati, OH
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD
Status: Enrolling
Updated: 9/7/2017
GSK Investigational Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD
Status: Enrolling
Updated:  9/7/2017
GSK Investigational Site
mi
from
Medford, OR
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD
Status: Enrolling
Updated: 9/7/2017
GSK Investigational Site
mi
from
Medford, OR
Click here to add this to my saved trials
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD
Status: Enrolling
Updated:  9/7/2017
GSK Investigational Site
mi
from
Gaffney, SC
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD
Status: Enrolling
Updated: 9/7/2017
GSK Investigational Site
mi
from
Gaffney, SC
Click here to add this to my saved trials
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD
Status: Enrolling
Updated:  9/7/2017
GSK Investigational Site
mi
from
Greenville, SC
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD
Status: Enrolling
Updated: 9/7/2017
GSK Investigational Site
mi
from
Greenville, SC
Click here to add this to my saved trials
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD
Status: Enrolling
Updated:  9/7/2017
GSK Investigational Site
mi
from
Rock Hill, SC
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD
Status: Enrolling
Updated: 9/7/2017
GSK Investigational Site
mi
from
Rock Hill, SC
Click here to add this to my saved trials
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD
Status: Enrolling
Updated:  9/7/2017
GSK Investigational Site
mi
from
Spartanburg, SC
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD
Status: Enrolling
Updated: 9/7/2017
GSK Investigational Site
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD
Status: Enrolling
Updated:  9/7/2017
GSK Investigational Site
mi
from
Union, SC
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD
Status: Enrolling
Updated: 9/7/2017
GSK Investigational Site
mi
from
Union, SC
Click here to add this to my saved trials
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD
Status: Enrolling
Updated:  9/7/2017
GSK Investigational Site
mi
from
Morgantown, WV
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD
Status: Enrolling
Updated: 9/7/2017
GSK Investigational Site
mi
from
Morgantown, WV
Click here to add this to my saved trials
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD
Status: Enrolling
Updated:  9/7/2017
GSK Investigational Site
mi
from
Ciudad Autonoma de Buenos Aires,
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD
Status: Enrolling
Updated: 9/7/2017
GSK Investigational Site
mi
from
Ciudad Autonoma de Buenos Aires,
Click here to add this to my saved trials
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
mi
from
Jasper, AL
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
mi
from
Jasper, AL
Click here to add this to my saved trials
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
mi
from
Glendale, AZ
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
mi
from
Glendale, AZ
Click here to add this to my saved trials
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
mi
from
Fountain Valley, CA
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
mi
from
Fullerton, CA
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
mi
from
Fullerton, CA
Click here to add this to my saved trials
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
mi
from
Los Angeles, CA
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
mi
from
Riverside, CA
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
mi
from
Riverside, CA
Click here to add this to my saved trials
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
mi
from
Roseville, CA
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
mi
from
Roseville, CA
Click here to add this to my saved trials
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
mi
from
San Diego, CA
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
mi
from
Brandon, FL
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
mi
from
Brandon, FL
Click here to add this to my saved trials
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
mi
from
Panama City, FL
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
mi
from
Panama City, FL
Click here to add this to my saved trials
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
mi
from
South Miami, FL
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
mi
from
South Miami, FL
Click here to add this to my saved trials
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
mi
from
Coeur d'Alene, ID
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
mi
from
Coeur d'Alene, ID
Click here to add this to my saved trials
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
mi
from
Madisonville, KY
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
mi
from
Madisonville, KY
Click here to add this to my saved trials
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
mi
from
Lafayette, LA
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
mi
from
Lafayette, LA
Click here to add this to my saved trials
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
mi
from
Sunset, LA
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
mi
from
Sunset, LA
Click here to add this to my saved trials
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
mi
from
Saint Charles, MO
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
mi
from
Saint Charles, MO
Click here to add this to my saved trials
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
mi
from
Charlotte, NC
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
mi
from
Charleston, SC
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
mi
from
Charleston, SC
Click here to add this to my saved trials
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
mi
from
Greenville, SC
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
mi
from
Greenville, SC
Click here to add this to my saved trials
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
mi
from
Spartanburg, SC
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
mi
from
Union, SC
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
mi
from
Union, SC
Click here to add this to my saved trials
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
mi
from
Houston, TX
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
mi
from
Abingdon, VA
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
mi
from
Abingdon, VA
Click here to add this to my saved trials
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
mi
from
Richmond, VA
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
mi
from
Richmond, VA
Click here to add this to my saved trials
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
mi
from
La Plata,
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
mi
from
La Plata,
Click here to add this to my saved trials
Lifestyle Physical Activity for People With COPD
Lifestyle Physical Activity for People With COPD
Status: Enrolling
Updated:  9/22/2017
University of Michigan, School of Nursing
mi
from
Ann Arbor, MI
Lifestyle Physical Activity for People With COPD
Lifestyle Physical Activity for People With COPD
Status: Enrolling
Updated: 9/22/2017
University of Michigan, School of Nursing
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) and Domestic Endotoxin (CODE)
COpd and Domestic Endotoxin (CODE)
Status: Enrolling
Updated:  9/29/2017
Johns Hopkins Asthma and Allergy Center
mi
from
Baltimore, MD
Chronic Obstructive Pulmonary Disease (COPD) and Domestic Endotoxin (CODE)
COpd and Domestic Endotoxin (CODE)
Status: Enrolling
Updated: 9/29/2017
Johns Hopkins Asthma and Allergy Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated:  10/5/2017
Clinical Research Facility
mi
from
Andalusia, AL
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated: 10/5/2017
Clinical Research Facility
mi
from
Andalusia, AL
Click here to add this to my saved trials
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated:  10/5/2017
Clinical Research Facility
mi
from
Birmingham, AL
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated: 10/5/2017
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated:  10/5/2017
Clinical Research Facility
mi
from
Foley, AL
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated: 10/5/2017
Clinical Research Facility
mi
from
Foley, AL
Click here to add this to my saved trials
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated:  10/5/2017
Clinical Research Facility
mi
from
Jasper, AL
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated: 10/5/2017
Clinical Research Facility
mi
from
Jasper, AL
Click here to add this to my saved trials